“‘tirzepatide’ Tag”,2021-01-27 (gravitostat, semaglutide)⁠:

Bibliography for tag longevity/glp/tirzepatide, most recent first: 1 related tag, 25 annotations, & 11 links (parent).

• See Also
• Links
  • “Tirzepatide for Heart Failure With Preserved Ejection Fraction and Obesity”, Packer et al 2024
  • “Tirzepatide for Obesity Treatment and Diabetes Prevention”, Jastreboff et al 2024
  • “Shady Drugmaker Used Code Words to Sell Knockoff Weight-Loss Drug Tirzepatide: Lawsuit”
  • “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity”, Rodriguez et al 2024
  • “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity”, Malhotra et al 2024
  • “Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020^–₃2023”, Lee et al 2024
  • “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial”, Aronne et al 2023
  • “Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults With Overweight and Obesity in the US: A Real-World Evidence Study”, Rodriguez et al 2023
  • “Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial”, Wadden et al 2023
  • “A Revolution in Obesity Treatment”, Lingvay & Agarwal2023
  • “Goodbye, Ozempic: A New Class of Drugs Is Transforming Obesity Care. They Are Not All the Same”, Engber2023
  • “Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): a Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial”, Garvey et al 2023
  • “Lilly’s Tirzepatide Achieved up to 15.7% Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes in SURMOUNT-2”, Lilly2023
  • “Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-Mono): a Double-Blind, Multicentre, Randomized, Phase 3 Trial”, Inagaki et al 2022
  • “Tirzepatide Once Weekly for the Treatment of Obesity”, Jastreboff et al 2022
  • “FDA Approves Lilly’s Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, Lilly2022
  • “Lilly’s Tirzepatide Delivered up to 22.5% Weight Loss in Adults With Obesity or Overweight in SURMOUNT-1”, Lilly & Company2022
  • “Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial”, Dahl et al 2022
  • “Anti-Obesity Drug Discovery: Advances and Challenges”, Müller et al 2021
  • “Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomized, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial”, Prato et al 2021
  • “Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec As Add-On to Metformin With or without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): a Randomized, Open-Label, Parallel-Group, Phase 3 Trial”, Ludvik et al 2021
  • “Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”, Frías et al 2021
  • “Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): a Double-Blind, Randomized, Phase 3 Trial”, Rosenstock et al 2021
  • “Risk of Major Adverse Cardiovascular Events and All-Cause Mortality under Treatment With GLP-1 RAs or the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Overweight or Obese Adults without Diabetes: a Systematic Review and Meta-Analysis”
  • “Society Is Fixed, Biology Is Mutable”
  • Sort By Magic
    • tirzepatide-revolution
    • tirzepatide-obesity
    • GLP-1-agonist
  • Wikipedia
• Miscellaneous
• Bibliography